Update on Lung Cancer Treatment Focused on Adenocarcinoma

Keimyung Medical Journal 2012;31(1):36-44.

폐암 치료의 최신 지견; 폐선암을 중심으로

최원일

Abstract

Last 20 years; great progress has been made in the care of advanced non-small cell lung cancer; especially adenocarcinoma. One year survival of advanced non-small cell lung cancer increases from 30% to 55%. Third-generation regimens with or without front-line targeted agents; or with efficient second- and third line low toxicity therapies may contribute improving survival. The emergence of targeted therapy in first- and second-line settings has spectacularly changed the natural history of disease especially EGFR mutated cancer; leading to dramatically prolonged overall survival. Maintenance therapy; either with targeted agents or cytotoxic agents; also improved survival for larger groups of non-small cell lung cancer.

Key Words: Adenocarcinoma, Nonsmall cell lung cancer, Targeted therapy